News
CMMB
1.270
+6.72%
0.080
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Chemomab Therapeutics Ltd. Released topline results from the Phase 2 SPRING trial assessing its monoclonal antibody, CM-101, in patients with primary sclerosing cholangitis. The drug showed significant improvement in liver stiffness. The company also announced a $10 million investment in public equity.
Benzinga · 1d ago
Chemomab falls on private placement despite mid-stage win for lead asset
Seeking Alpha · 1d ago
Chemomab’s CM-101 Shows Promise in PSC Trial
TipRanks · 1d ago
CHEMOMAB - EXPECTS PIPE TO EXTEND CASH RUNWAY THROUGH BEGINNING OF 2026
Reuters · 1d ago
BRIEF-Chemomab Therapeutics Announces Positive Phase 2 Trial Results
Chemomab Therapeutics Ltd announces positive Phase 2 trial results. Company says its CM-101 drug has shown positive results in a clinical trial. The drug is being developed to treat liver strain in patients with advanced liver cancer. Company says the drug is in phase 2 of the trial.
Reuters · 1d ago
CHEMOMAB THERAPEUTICS LTD - CM-101 IMPROVES LIVER STIFFNESS IN PSC
Reuters · 1d ago
Chemomab Therapeutics Announces $10 Million Private Placement
Chemomab Therapeutics Ltd. Is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. The company has entered into a securities purchase agreement for a private investment in public equity. The deal is expected to result in gross proceeds of approximately $10 million.
Barchart · 1d ago
Weekly Report: what happened at CMMB last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at CMMB last week (0708-0712)?
Weekly Report · 07/15 11:17
Weekly Report: what happened at CMMB last week (0701-0705)?
Weekly Report · 07/08 11:18
Weekly Report: what happened at CMMB last week (0624-0628)?
Weekly Report · 07/01 11:19
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
NASDAQ · 06/27 16:00
CHEMOMAB Granted U.S. Patent #12018074: Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases
Benzinga · 06/25 19:43
Weekly Report: what happened at CMMB last week (0617-0621)?
Weekly Report · 06/24 11:27
Chemomab Therapeutics (CMMB) Gets a Buy from Roth MKM
TipRanks · 06/21 11:45
Maxim Group Sticks to Its Buy Rating for Chemomab Therapeutics (CMMB)
TipRanks · 06/19 17:55
CHEMOMAB THERAPEUTICS ANNOUNCES NEW PUBLICATIONS REINFORCING THE CLINICAL POTENTIAL OF ITS CCL24-NEUTRALIZING ANTIBODY CM-101 IN PRIMARY SCLEROSING CHOLANGITIS
Reuters · 06/18 11:00
Weekly Report: what happened at CMMB last week (0610-0614)?
Weekly Report · 06/17 11:17
Chemomab Shareholders Approve Key Resolutions
TipRanks · 06/12 20:58
More
Webull provides a variety of real-time CMMB stock news. You can receive the latest news about Chemomab Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CMMB
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.